{"id":"CHEMBL1090771","canonicalSmiles":"NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1","inchiKey":"XEAOPVUAMONVLA-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AVAGACESTAT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Avagacestat","BMS 708163","BMS-708163","BMS-708163-01","BMS-70816301"],"crossReferences":{"drugbank":["DB11893"]},"linkedTargets":{"rows":["ENSG00000205155","ENSG00000138613","ENSG00000162736","ENSG00000080815","ENSG00000143801","ENSG00000117362"],"count":6},"linkedDiseases":{"rows":["MONDO_0004975"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1092824","canonicalSmiles":"O=C(Nc1nccs1)C(=O)NC1CCCC1","inchiKey":"BJHPYHUDDCVBNG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1092824","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07591"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL119549","canonicalSmiles":"O=C(Nc1ccc(-c2nn[nH]n2)cc1)c1ccc(-c2nn[nH]n2)cc1","inchiKey":"VXEBMQZDPONDFB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANDOLAST","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Andolast","Cr2039"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL1200845","canonicalSmiles":"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1","inchiKey":"MUQNGPZZQDCDFT-JNQJZLCISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HALCINONIDE","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Halog","Halog-e"],"synonyms":["Halcinonide","NSC-758413","SO 18566","SO-18566","SQ 18566","SQ-18566"],"crossReferences":{"DailyMed":["halcinonide"],"PubChem":["144204081","170465389","56463097"],"Wikipedia":["Halcinonide"],"drugbank":["DB06786"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0000701"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for skin disease."}
{"id":"CHEMBL1200914","canonicalSmiles":"CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl","inchiKey":"ZZIZZTHXZRDOFM-XFULWGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAMSULOSIN HYDROCHLORIDE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL836","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alphacard mr","Bazetham mr","Contiflo xl","Cositam xl","Diffundox","Faramsil","Flectone xl","Flomax","Flomax mr","Flomax relief mr","Flomaxtra xl","Galebon","Losinate mr","Maxtron","Morvesin xl","Omnic mr","Pamsvax xl","Petyme","Pinexel pr","Prosurin xl","Stronazon","Tabphyn mr","Tamfrex xl","Tamsulosin hydrochloride","Tamurex"],"synonyms":["Harnal","LY-253351","LY253351","R-(-)-YM-12617","Tamsulosin hcl","Tamsulosin hydrochloride","YM-12617-1","YM-617","YM617"],"crossReferences":{"DailyMed":["tamsulosin%20hydrochloride"],"PubChem":["144205999","170464826"],"chEBI":["9399"]},"linkedTargets":{"rows":["ENSG00000171873","ENSG00000170214","ENSG00000120907"],"count":3},"linkedDiseases":{"rows":["HP_0000016","EFO_0004253","EFO_0005323","EFO_1001228","EFO_0000284","EFO_0000536","EFO_0003830","HP_0000011","EFO_0001663","EFO_0000537","HP_0011277"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for prostate carcinoma and benign prostatic hyperplasia and has 5 investigational indications."}
{"id":"CHEMBL1200946","canonicalSmiles":"CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C","inchiKey":"JKWKMORAXJQQSR-MOPIKTETSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NANDROLONE DECANOATE","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Deca-durabolin","Durabolin","Nandrolone decanoate"],"synonyms":["Nandrolone decanoate","Nandrolone decanoate ciii"],"crossReferences":{"PubChem":["144205191","170464711","29215336"],"drugbank":["DB08804"],"chEBI":["7467"]},"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["EFO_0003966","EFO_0007312","EFO_0008572","EFO_0003964"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for eye disease and has 3 investigational indications."}
{"id":"CHEMBL1201038","canonicalSmiles":"CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12","inchiKey":"YZODJQFXMFEJRM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACRISORCIN","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Akrinol"],"synonyms":["Acrisorcin","NSC-758691","SCH 7056","SCH-7056"],"crossReferences":{"DrugCentral":["5103"],"PubChem":["26748936"],"Wikipedia":["Acrisorcin"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201413","drugType":"Protein","blackBoxWarning":false,"name":"TECHNETIUM TC 99M DEPREOTIDE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Neo tect kit"],"synonyms":["Technetium (99Mtc) Depreotide","Technetium (99mtc) depreotide","Technetium tc 99m depreotide","Technetium tc-99m depreotide"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1999."}
{"id":"CHEMBL1201528","drugType":"Protein","blackBoxWarning":false,"name":"VASOPRESSIN TANNATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pitressin tannate"],"synonyms":["Vasopressin tannate"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201648","drugType":"Enzyme","blackBoxWarning":false,"name":"AMYLASE (PANCRELIPASE)","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Amylase","Amylase (pancrelipase)","E1100"],"crossReferences":{"DailyMed":["amylase%20(pancrelipase)"]},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 investigational indications."}
{"id":"CHEMBL1208155","canonicalSmiles":"COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F","inchiKey":"HEAUOKZIVMZVQL-VWLOTQADSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELAGOLIX","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Elagolix","NBI-56418"],"crossReferences":{"DailyMed":["elagolix%20sodium"],"drugbank":["DB11979"]},"childChemblIds":["CHEMBL502182"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0003099","EFO_0000731","EFO_0001065","EFO_0000660"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for endometriosis and has 3 investigational indications."}
{"id":"CHEMBL121626","canonicalSmiles":"Cc1c(Cl)cccc1Nc1ccccc1C(=O)O","inchiKey":"YEZNLOUZAIOMLT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOLFENAMIC ACID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Clotam","Clotam rapid"],"synonyms":["N-(3-chloro-o-tolyl)anthranilic","NSC-757873","Tolfenamic acid"],"crossReferences":{"PubChem":["104171320","11112613","144204121","170465638","26746981","855759"],"Wikipedia":["Tolfenamic_acid"],"drugbank":["DB09216"],"chEBI":["32243"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 2 investigational indications."}
{"id":"CHEMBL121663","canonicalSmiles":"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21.[Cl-].[Cl-]","inchiKey":"LTNZEXKYNRNOGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEQUALINIUM CHLORIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL333826","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dequacets","Dequadin","Fluomizin","Labosept"],"synonyms":["BAQD 10","BAQD-10","Decamine","Dekamin","Dequalinium chloride","Dequalinium dichloride","GNF-PF-5483","NSC-166454","Nordman"],"crossReferences":{"PubChem":["144203679","26747489","26747490","50106101"],"Wikipedia":["Dequalinium"],"chEBI":["31466"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL1230893","canonicalSmiles":"CC(=O)NCCc1c[nH]cn1","inchiKey":"XJWPISBUKWZALE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1230893","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["49674566"],"drugbank":["DB04622"],"chEBI":["28483"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232261","canonicalSmiles":"CS(=O)(=O)c1cccc(-c2cc(N3C[C@H](c4cc(F)c(F)cc4F)[C@@H](N)C3)ncn2)c1","inchiKey":"OAWGQHXWGXOUKV-BEFAXECRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232261","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07666"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232804","canonicalSmiles":"O=C(NCP(=O)(O)O)OCc1ccccc1","inchiKey":"WUNKRZNFNIYEPN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(BENZYLOXYCARBONYLAMINO)METHYLPHOSPHONIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02642"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232952","canonicalSmiles":"C=C1C[C@]23C[C@@]1(O)CC[C@H]2[C@@]12C=C[C@H](O)[C@@](C)(C(=O)O1)[C@H]2[C@@H]3C(=O)O","inchiKey":"IXORZMNAPKEEDV-OBDJNFEBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GIBBERELLIN A3","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(+)-Gibberellic Acid"],"crossReferences":{"PubChem":["144209250","144213340","49826122","56463589","78420"],"drugbank":["DB07814"],"chEBI":["28833"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1233202","canonicalSmiles":"C[C@@H](Oc1ccc(Oc2ncc(C(F)(F)F)cc2Cl)cc1)C(=O)O","inchiKey":"GOCUAJYOYBLQRH-MRVPVSSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HALOXYFOP-R-METHYL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07870"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234579","canonicalSmiles":"N#[N+][O-]","inchiKey":"GQPLMRYTRLFLPF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NITROUS OXIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Entonox"],"synonyms":["Dinitrogen monoxide","Dinitrogen oxide","Dinitrogenii oxidum","E-942","FEMA NO. 2779","Factitious air","INS NO.942","INS-942","Laughing gas","Nitrogen monoxide","Nitrogen oxide (n(sub 2)o)","Nitrogen protoxide","Nitrogenum oxygenatum","Nitrous Oxide","Nitrous oxide","Protoxide of nitrogen"],"crossReferences":{"Wikipedia":["Nitrous_oxide"],"drugbank":["DB06690"],"chEBI":["17045"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 15 investigational indications."}
{"id":"CHEMBL1235931","canonicalSmiles":"CC(=O)CCC(=O)O","inchiKey":"JOOXCMJARBKPKM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVULINIC ACID","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FEMA NO. 2627","Laevulinic acid","Levulinic acid","NSC-3716"],"crossReferences":{"PubChem":["144208681","144213046","29217860"],"Wikipedia":["Levulinic_acid"],"drugbank":["DB02239"],"chEBI":["45630"]},"childChemblIds":["CHEMBL3707302","CHEMBL3186421","CHEMBL2106516"],"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL1288810","canonicalSmiles":"OC[C@@H](O)CN1CCN(c2ccccc2)CC1","inchiKey":"PTVWPYVOOKLBCG-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVODROPROPIZINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-)-dropropizine","(s)-(-)-dropropizine","Danka","Dipropizine, (s)-isomer","Dropropizine s-form","Dropropizine, (s)-","L-dropropizine","Levodropropizine","Levopront","Levotuss","Rapitux"],"crossReferences":{"PubChem":["11112639"],"drugbank":["DB12472"],"chEBI":["82722"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL135626","canonicalSmiles":"CC","inchiKey":"OTMSDBZUPAUEDD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHANE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ethane","Venoterpine"],"crossReferences":{"Wikipedia":["Ethane"],"chEBI":["42266"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL13968","canonicalSmiles":"CCCCN","inchiKey":"HQABUPZFAYXKJW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTYLAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Aminobutane","NBA"],"crossReferences":{"PubChem":["144211448"],"Wikipedia":["N-Butylamine"],"drugbank":["DB03659"],"chEBI":["43799"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1631694","canonicalSmiles":"CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1","inchiKey":"MIWWSGDADVMLTG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FEXINIDAZOLE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fexinidazole","HOE 239","HOE-239"],"crossReferences":{"drugbank":["DB12265"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 4 investigational indications."}
{"id":"CHEMBL1688530","canonicalSmiles":"CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O","inchiKey":"VHFGEBVPHAGQPI-LXKZPTCJSA-N","drugType":"Unknown","blackBoxWarning":false,"name":"ORITAVANCIN","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["LY-333328","LY333328","Oritavancin"],"crossReferences":{"DailyMed":["oritavancin%20diphosphate"],"drugbank":["DB04911"],"chEBI":["82699"]},"childChemblIds":["CHEMBL3989766"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for bacterial disease and infection and has 4 investigational indications."}
{"id":"CHEMBL169896","canonicalSmiles":"Cc1nc2ccc3ccc(CNc4ccc5c(c4)CN([C@@H](CCC(=O)O)C(=O)O)C5=O)cc3c2c(=O)[nH]1","inchiKey":"BRVFNEZMTRVUGW-QFIPXVFZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OSI-7904","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gw-1843","OSI-7904L","Osi 7904","Osi 7904l","Osi-7904","Osi-7904l","TCMDC-131928"],"linkedTargets":{"rows":["ENSG00000176890"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0006859","EFO_1001951"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL170797","canonicalSmiles":"CCOC(=O)C1(c2ccccc2)CCCN(C)CC1","inchiKey":"WGJHHMKQBWSQIY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHOHEPTAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ethoheptazine"],"crossReferences":{"Wikipedia":["Ethoheptazine"],"drugbank":["DB08988"]},"childChemblIds":["CHEMBL3186813","CHEMBL1201887"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1742987","drugType":"Antibody","blackBoxWarning":false,"name":"ATINUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ATI-355","Atinumab"],"linkedTargets":{"rows":["ENSG00000115310"],"count":1},"linkedDiseases":{"rows":["EFO_1001919"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1743010","drugType":"Antibody","blackBoxWarning":false,"name":"ELOTUZUMAB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BMS-901608","Elotuzumab","Empliciti","HULUC63","PDL-063","PDL063"],"crossReferences":{"DailyMed":["elotuzumab"],"DrugCentral":["5072"]},"linkedTargets":{"rows":["ENSG00000026751"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003073","EFO_0006475","MONDO_0017287","EFO_0001378","MONDO_0044881","Orphanet_85443"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for multiple myeloma and neoplasm and has 5 investigational indications."}
{"id":"CHEMBL1756","canonicalSmiles":"C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O","inchiKey":"ADFOJJHRTBFFOF-RBRWEJTLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESTRAMUSTINE PHOSPHATE","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Estracyt"],"synonyms":["Estramustine 17-(dihydrogen phosphate)","Estramustine phosphate","Ls 299","Ls-299","NSC-89199"],"crossReferences":{"DailyMed":["estramustine%20phosphate%20sodium"],"PubChem":["144206584"],"drugbank":["DB14674"],"chEBI":["68643"]},"childChemblIds":["CHEMBL1200721"],"linkedTargets":{"rows":["ENSG00000140009"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000673","MONDO_0007254","EFO_0000574","EFO_0000313","MONDO_0002367","MONDO_0008315"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for carcinoma and neoplasm and has 6 investigational indications."}
{"id":"CHEMBL176045","canonicalSmiles":"COc1ccc2cc1Oc1ccc(cc1)C[C@H]1c3cc(c(OC)cc3CCN1C)Oc1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3","inchiKey":"WVTKBKWTSCPRNU-KYJUHHDHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FANCHININ","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-77037"],"crossReferences":{"PubChem":["118059","124883161","124883162","124883163","124883165","26725273","26754345","26754346","398101","56463074"],"Wikipedia":["Tetrandrine"],"drugbank":["DB14066"],"chEBI":["49"]},"childChemblIds":["CHEMBL4160643"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL18901","canonicalSmiles":"Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1","inchiKey":"BNFRJXLZYUTIII-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EFAPROXIRAL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Efaproxiral","RSR-13","RSR13"],"crossReferences":{"Wikipedia":["Efaproxiral"],"drugbank":["DB08486"]},"childChemblIds":["CHEMBL2107744"],"linkedTargets":{"rows":["ENSG00000244734","ENSG00000188536","ENSG00000206172"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0008903","MONDO_0007254","MONDO_0024880","EFO_1000158"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1908305","canonicalSmiles":"C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[S@@+]([O-])C3)S[C@H]12","inchiKey":"FLSUCZWOEMTFAQ-PRBGKLEPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULOPENEM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CP-70,429","CP-70429","Sulopenem"],"crossReferences":{"drugbank":["DB15284"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL192","canonicalSmiles":"CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12","inchiKey":"BNRNXUUZRGQAQC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SILDENAFIL","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nipatra","Revatio","Viagra","Vizarsin"],"synonyms":["Aphrodil","HIP-0908","HIP0908","Patrex","Sildenafil","Sildenafil actavis","Sildenafil ratiopharm","Sildenafil teva","UK-92480"],"crossReferences":{"DailyMed":["sildenafil%20citrate"],"PubChem":["26748898","50085897"],"drugbank":["DB00203"],"chEBI":["9139"]},"childChemblIds":["CHEMBL1737"],"linkedTargets":{"rows":["ENSG00000138735"],"count":1},"linkedDiseases":{"rows":["EFO_0008493","MONDO_0024647","EFO_0003777","EFO_0001361","Orphanet_98895","EFO_0009197","HP_0000802","EFO_0000266","HP_0001298","EFO_1001145","EFO_0003913","EFO_0004714","EFO_1000824","EFO_1001134","EFO_0009429","EFO_0000400","Orphanet_654","EFO_0000198","EFO_0009441","MONDO_0005149","HP_0200042","EFO_0004145","EFO_1001103","HP_0001919","EFO_0008560","EFO_1001986","EFO_0000701","MONDO_0002013","EFO_0009085","MONDO_0008315","Orphanet_98896","EFO_0001422","EFO_0000404","MONDO_0100096","HP_0100607","EFO_0000341","EFO_0003830","EFO_0000516","EFO_0004225","EFO_0000668","MONDO_0021640","EFO_0006862","MONDO_0005090","Orphanet_232","EFO_0001365","EFO_0004234","EFO_0000768","EFO_0000464","Orphanet_586","EFO_0000284","EFO_0000373","EFO_0000495","MONDO_0004933","EFO_0002950","EFO_1000783","Orphanet_70589","EFO_0003144","EFO_1001996","MONDO_0005180","EFO_0000712","EFO_1001993","HP_0000618","EFO_0003047","EFO_0003917","EFO_1001893","EFO_0000717","EFO_0002546","EFO_0000616","EFO_1001017","EFO_0000545","HP_0002140","Orphanet_422","EFO_0001645","HP_0001655","EFO_0009200","HP_0200023","EFO_0003818","EFO_0001073","EFO_0003060","EFO_0000537","EFO_1000954","EFO_0000195","EFO_1001827","EFO_0003827","EFO_0011023","HP_0000020","HP_0025116","MONDO_0043510","EFO_0003833","EFO_0004540","EFO_0000519","EFO_0004265","EFO_1000899","MONDO_0005475"],"count":94},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 6 approved and 76 investigational indications."}
{"id":"CHEMBL1944785","canonicalSmiles":"CCN(CC)C(=O)[C@H]1CCCc2c1c1c(OC)cccc1n2CC[18F]","inchiKey":"ZVDVQPLDTTXLKI-LSKWOKDISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1944785","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2068835","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB15380"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2017179","canonicalSmiles":"Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1","inchiKey":"IHIUGIVXARLYHP-YBXDKENTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EVACETRAPIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Evacetrapib","LY-2484595","LY2484595"],"crossReferences":{"Wikipedia":["Evacetrapib"],"drugbank":["DB11655"]},"linkedTargets":{"rows":["ENSG00000087237"],"count":1},"linkedDiseases":{"rows":["HP_0003124","MONDO_0021187","EFO_0000319","Orphanet_309005"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2068971","canonicalSmiles":"C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@]1(O)CC[C@]2(O)c1ccoc1","inchiKey":"AEAPORIZZWBIEX-DTBDINHYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROSTAFUROXIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Rostafuroxin"],"crossReferences":{"drugbank":["DB12350"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL207225","canonicalSmiles":"O=C(O)CCc1c[nH]c2ccccc12","inchiKey":"GOLXRNDWAUTYKT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INDOLYLPROPIONIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3-Indolepropionicacid","Indole-3-Propionic Acid"],"crossReferences":{"drugbank":["DB02758"],"chEBI":["43580"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2079587","canonicalSmiles":"C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O","inchiKey":"LKAJKIOFIWVMDJ-IYRCEVNGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"STANOZOLOL","yearOfFirstApproval":1962,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Stromba","Tevabolin","Winstrol"],"synonyms":["Androstanazol","Androstanazole","NSC-233046","NSC-43193","Stanozolol","Stanozolol ciii","WIN 14833","WIN-14833","Winstrol","Winstrol Depot"],"crossReferences":{"PubChem":["170465251"],"drugbank":["DB06718"],"chEBI":["9249"]},"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["EFO_0000198"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962."}
{"id":"CHEMBL2095222","drugType":"Enzyme","blackBoxWarning":false,"name":"OCRIPLASMIN","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Jetrea","MICROPLASMIN","Microplasmin (synthetic human)","Ocriplasmin","Recombinant human microplasmin"],"crossReferences":{"DrugCentral":["5004"]},"linkedTargets":{"rows":["ENSG00000115414","ENSG00000172037","ENSG00000060718","ENSG00000130702","ENSG00000168542","ENSG00000188153","ENSG00000164692","ENSG00000206384","ENSG00000204262","ENSG00000172752","ENSG00000169031","ENSG00000196569","ENSG00000112769","ENSG00000050555","ENSG00000197565","ENSG00000142173","ENSG00000058085","ENSG00000204291","ENSG00000130635","ENSG00000171502","ENSG00000139219","ENSG00000091128","ENSG00000196878","ENSG00000101680","ENSG00000134871","ENSG00000108821","ENSG00000204248","ENSG00000163359","ENSG00000081052","ENSG00000142156","ENSG00000080573","ENSG00000053747","ENSG00000215018","ENSG00000091136","ENSG00000135862","ENSG00000196739","ENSG00000182871","ENSG00000187498"],"count":38},"linkedDiseases":{"rows":["EFO_0009606","EFO_0003966","EFO_1001231","EFO_1001028","EFO_0000712","EFO_1001157","EFO_0003907","EFO_0009321"],"count":8},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for eye disease and has 6 investigational indications."}
{"id":"CHEMBL2104745","canonicalSmiles":"CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1","inchiKey":"HIUPRQPBWVEQJJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PAGOCLONE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IP 456","IP-456","Pagoclone","RP 62955","RP-62955"],"crossReferences":{"drugbank":["DB04903"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2105734","canonicalSmiles":"COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O.[Br-]","inchiKey":"QBIYUDDJPRGKNJ-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SEPANTRONIUM BROMIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2110734","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sepantronium bromide","YM 155","YM-155","YM155"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL2106179","canonicalSmiles":"O=C1CC[C@H](C(=O)N2CCCCC2)N1","inchiKey":"GOWRRBABHQUJMX-MRVPVSSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FASORACETAM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AEVI-001","AEVI001","Aevi-001","Fasoracetam","LAM-105","LAM-105 ANHYDROUS","LAM105 ANHYDROUS","NFC-1 ANHYDROUS","NFC1 ANHYDROUS","NS-105","NS105"],"crossReferences":{"PubChem":["144206891"],"chEBI":["31592"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2106755","canonicalSmiles":"O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.[Mg+2]","inchiKey":"MQHWFIOJQSCFNM-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"MAGNESIUM SALICYLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"DrugCentral":["4510"],"drugbank":["DB01397"],"chEBI":["6640"]},"childChemblIds":["CHEMBL3989810"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106798","canonicalSmiles":"CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O","inchiKey":"CLUKHUGGXSIGRX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NERAMEXANE MESYLATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2110954","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Neramexane mesilate","Neramexane mesylate"],"linkedTargets":{"rows":["ENSG00000161509","ENSG00000273079","ENSG00000183454","ENSG00000116032","ENSG00000105464","ENSG00000174343","ENSG00000129749","ENSG00000176884","ENSG00000198785"],"count":9},"linkedDiseases":{"rows":["HP_0000360"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2107106","canonicalSmiles":"C#CC(C)(CC)OC(=O)c1ccccc1C(=O)O","inchiKey":"CZGIRAWWWHPJHM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHTHALOFYNE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ftalofyne","NSC-25614","Phthalofyne"],"crossReferences":{"PubChem":["170466477"],"drugbank":["DB11449"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107772","canonicalSmiles":"C[C@@H](c1ccc(-c2ccccc2)c(F)c1)c1cc(NC(=N)N2CCOCC2)on1","inchiKey":"MYTIJGWONQOOLC-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIMACALIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Rimacalib","SMP-114","Smp-114"],"crossReferences":{"drugbank":["DB12571"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2107884","drugType":"Antibody","blackBoxWarning":true,"name":"RESLIZUMAB","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cinqaero","Cinqair","Cinquil"],"synonyms":["CEP-38072","DCP 835","DCP-835","Reslizumab","SCH 55700","SCH-55700","SCH55700"],"crossReferences":{"DailyMed":["reslizumab"],"DrugCentral":["5093"]},"linkedTargets":{"rows":["ENSG00000113525"],"count":1},"linkedDiseases":{"rows":["EFO_0004232","MONDO_0004938","HP_0006536","EFO_1000729","EFO_0007486","EFO_0009661","MONDO_0004979","EFO_1001467"],"count":8},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for asthma and airway obstruction and has 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108035","drugType":"Unknown","blackBoxWarning":true,"name":"INCOBOTULINUMTOXINA","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Incobotulinumtoxina","RTI-150","RTI150"],"linkedTargets":{"rows":["ENSG00000132639"],"count":1},"linkedDiseases":{"rows":["HP_0001257","HP_0001337","EFO_1001219","Orphanet_93955","HP_0012076","MONDO_0003441","EFO_0004234","HP_0009762","HP_0000473","EFO_0005422","EFO_0003843","EFO_1001909","Orphanet_1866","EFO_1000760","MONDO_0005180","EFO_0000712","HP_0002061","EFO_1000781","HP_0006986","EFO_0003108","HP_0025267","EFO_0003877"],"count":22},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108314","drugType":"Protein","blackBoxWarning":false,"name":"NEPIDERMIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epidermal growth factor","Nepidermin"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2108499","drugType":"Enzyme","blackBoxWarning":false,"name":"LANOTEPLASE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7-l-glutamine-245-l-methionine","BMS-200980","Lanoteplase","SUN 9216","SUN-9216"],"description":"Enzyme drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2108875","drugType":"Unknown","blackBoxWarning":false,"name":"TETANUS TOXOID","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tetanus toxoid"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications."}
{"id":"CHEMBL2108904","drugType":"Unknown","blackBoxWarning":false,"name":"BATROXOBIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Batroxobin","Defibrase"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109229","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"OBLIMERSEN SODIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Genasense"],"synonyms":["Augmerosen","D-G3139","G-3139","G3139","Oblimersen","Oblimersen sodium"],"linkedTargets":{"rows":["ENSG00000171791"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","EFO_0000756","EFO_0000681","MONDO_0007254","EFO_1001469","EFO_1001951","MONDO_0001187","EFO_0000565","EFO_0000339","EFO_0000389","MONDO_0008903","EFO_0004289","EFO_0009441","EFO_0000616","EFO_0006859","MONDO_0019457","MONDO_0008170","Orphanet_44890","EFO_0000403","MONDO_0007576","MONDO_0008315","MONDO_0002691","EFO_1001471","EFO_0006861","EFO_0000095","EFO_0000702","EFO_0000574","MONDO_0002367","MONDO_0018906","EFO_0001378"],"count":30},"description":"Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications."}
{"id":"CHEMBL2109357","drugType":"Antibody","blackBoxWarning":false,"name":"AVE-1642","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AVE-1642","AVE1642","Ave 1642","Ave-1642"],"linkedTargets":{"rows":["ENSG00000140443"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","MONDO_0018531","EFO_0001378"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2111086","canonicalSmiles":"N[C@@H](CCC(=O)N[C@@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(=O)N[C@@H](C(=O)O)c1ccccc1)C(=O)O","inchiKey":"OJLHWPALWODJPQ-QNWVGRARSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CANFOSFAMIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Canfosfamide"],"crossReferences":{"drugbank":["DB04972"]},"childChemblIds":["CHEMBL2107319"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL2181932","canonicalSmiles":"Cc1c(C(=O)Nc2ccc(S(C)(=O)=O)cc2)cn(CCO)c1-c1ccccc1C(F)(F)F","inchiKey":"NOSNHVJANRODGR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2181932","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB15207"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL222476","canonicalSmiles":"CSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1","inchiKey":"ZIGJZZDDPXRGTL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL222476","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04720"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2364652","drugType":"Antibody","blackBoxWarning":false,"name":"VANTICTUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["OMP-18R5","Vantictumab"],"linkedTargets":{"rows":["ENSG00000180340","ENSG00000177283","ENSG00000163251","ENSG00000155760","ENSG00000157240"],"count":5},"linkedDiseases":{"rows":["EFO_0002618","EFO_0000616","MONDO_0007254"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL256892","canonicalSmiles":"CC(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)c1nc2ccccc2s1","inchiKey":"VXDAVYUFYPFGDX-SNPRPXQTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RWJ-56423","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RWJ-56423"],"crossReferences":{"drugbank":["DB02812"]},"childChemblIds":["CHEMBL556199","CHEMBL124571"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL283800","canonicalSmiles":"CN(CC(=O)O)C(=N)N","inchiKey":"CVSVTCORWBXHQV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CREATINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cosmocair c 100","Creatine","Kreatinum","NSC-8752","Neotine"],"crossReferences":{"Wikipedia":["Creatine"],"drugbank":["DB00148"],"chEBI":["16919"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL284616","canonicalSmiles":"O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O","inchiKey":"CWVRJTMFETXNAD-JUHZACGLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROGENIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-cqa","Chlorogenic acid","Cp chlorogenic acid","Heriguard","NSC-407296","NSC-70861","Trans-5-o-caffeoylquinic acid","Trans-caffeic acid 5-o-d-quinate","Trans-chlorogenic acid"],"crossReferences":{"PubChem":["56463713"],"Wikipedia":["Chlorogenic_acid"],"drugbank":["DB12029"],"chEBI":["16112"]},"childChemblIds":["CHEMBL1590181"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL29188","canonicalSmiles":"COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC","inchiKey":"JQSAYKKFZOSZGJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LOMERIZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lomerizine"],"crossReferences":{"PubChem":["26757962"],"Wikipedia":["Lomerizine"],"drugbank":["DB14065"]},"childChemblIds":["CHEMBL1404407","CHEMBL2356978"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL301213","canonicalSmiles":"O=C(Nc1nccs1)c1cccc(CN2C(=O)N(CC3CC3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1","inchiKey":"HFLCERPZYCWLSZ-VKONIRKNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL301213","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04609"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3137339","drugType":"Cell","blackBoxWarning":false,"name":"ROMYELOCEL-L","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CLT-008","Romyelocel-l"],"description":"Cell drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3184906","canonicalSmiles":"CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1.O","inchiKey":"ALYUMNAHLSSTOU-PFBPGKLMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFPROZIL","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3301800","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cefprozil","Cefzil"],"synonyms":["BBS-1067","BMY-28100-03-800","BMY-28167","Cefprozil","Cefprozil e-form","Cefprozil monohydrate","NSC-759099"],"crossReferences":{"DailyMed":["cefprozil"],"PubChem":["144205284"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 1 investigational indication."}
{"id":"CHEMBL324846","canonicalSmiles":"CCCCCCCC(=O)O","inchiKey":"WWZKQHOCKIZLMA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTANOIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Caprylic acid","EDENOR C 8-98-100","FEMA NO. 2799","Kortacid-0899","N-octanoic acid","NSC-5024","Octanoic acid","Prifac-2901"],"crossReferences":{"PubChem":["144204596","144208477","144210663","17388833","17389655","85272331"],"Wikipedia":["Caprylic_acid"],"drugbank":["DB04519"],"chEBI":["28837"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL3301670","canonicalSmiles":"CN(C)CC(C)(C)OC(=O)C(O)(c1ccccc1)c1ccccc1.Cl","inchiKey":"QRHDDSUGMIAILK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIFEMERINE HYDROCHLORIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL3304486","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Germany"],"year":1986},"tradeNames":[],"synonyms":["Difemerine hcl","Difemerine hydrochloride","Luostyl"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in Germany  in 1986."}
{"id":"CHEMBL3348932","canonicalSmiles":"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C","inchiKey":"DUXZAXCGJSBGDW-HXUWFJFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DESFESOTERODINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-hydroxymethyltolterodine","Desfesoterodine","PNU-200577","Spm 7605"],"crossReferences":{"drugbank":["DB15578"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL34062","canonicalSmiles":"COc1cc(OC)cc(-c2nc(N)c(CN)c(-c3ccc(Cl)cc3Cl)n2)c1","inchiKey":"RCJFINNFYUNFGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL34062","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02004"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544919","canonicalSmiles":"N=C(N)NCCC[C@H](N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(=N)N)CC1","inchiKey":"HRDUUSCYRPOMSO-ROUUACIJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CIRAPARANTAG","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ciraparantag","PER-977","PER977"],"crossReferences":{"drugbank":["DB15199"]},"childChemblIds":["CHEMBL3544918"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545020","drugType":"Small molecule","blackBoxWarning":false,"name":"MBX-2044","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mbx-2044"],"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545086","drugType":"Small molecule","blackBoxWarning":false,"name":"LY2881835","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-2881835","LY2881835","Ly2881835"],"linkedTargets":{"rows":["ENSG00000126266"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545210","canonicalSmiles":"CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1.O=C(O)CC(O)(CC(=O)O)C(=O)O","inchiKey":"VOHOCSJONOJOSD-RQIKCBEZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SR16234","maximumClinicalTrialPhase":2,"parentId":"CHEMBL3545211","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HLX-801","SR-16234","Sr16234","TAS-108","TS-108"],"linkedTargets":{"rows":["ENSG00000091831"],"count":1},"linkedDiseases":{"rows":["MONDO_0007254"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545240","drugType":"Small molecule","blackBoxWarning":false,"name":"CLX-0921","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clx-0921","THR-0921"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545265","drugType":"Small molecule","blackBoxWarning":false,"name":"MLN-0415","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mln-0415"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3547132","canonicalSmiles":"N[C@@H](Cc1cc(O)c(O)cc1F)C(=O)O","inchiKey":"PAXWQORCRCBOCU-LURJTMIESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUORODOPA","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"DailyMed":["fluorodopa%20f-18"],"chEBI":["49163"]},"childChemblIds":["CHEMBL3400972"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 investigational indications."}
{"id":"CHEMBL363392","canonicalSmiles":"CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O","inchiKey":"STPKWKPURVSAJF-LJEWAXOPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MARALIXIBAT","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["LUM-001 CATION","LUM001 CATION","Lopixibat","Maralixibat","Maralixibat cation"],"childChemblIds":["CHEMBL17879"],"linkedTargets":{"rows":["ENSG00000125255"],"count":1},"linkedDiseases":{"rows":["Orphanet_30391","EFO_0004268","HP_0000989","Orphanet_172","EFO_0001421","Orphanet_52","EFO_1001486"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alagille syndrome and pruritus and has 5 investigational indications."}
{"id":"CHEMBL363449","canonicalSmiles":"CC1CCc2c(N3CCC(O)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23","inchiKey":"JYJTVFIEFKZWCJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NADIFLOXACIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acuatim","Jinofloxacin","NSC-759622","Nadifloxacin","OPC 7251","OPC-7251"],"crossReferences":{"PubChem":["144205792","170465882","26758042","56463184"],"drugbank":["DB12447"],"chEBI":["31889"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3707223","canonicalSmiles":"CCOC(=O)C[N+]1(C)CC[C@@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1.[Br-]","inchiKey":"FIAFMTCUJCWADZ-JOFREBOKSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SOFPIRONIUM BROMIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL3707224","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BBI-4000","Sofpironium bromide"],"linkedTargets":{"rows":["ENSG00000180720","ENSG00000184984","ENSG00000133019","ENSG00000181072","ENSG00000168539"],"count":5},"linkedDiseases":{"rows":["HP_0000975"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3707370","canonicalSmiles":"CCC1(CC)C(=O)CCNC1=O","inchiKey":"RGEVWUKXWFOAID-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIPERIDIONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dihyprylone","NSC-75628","Piperidione"],"crossReferences":{"drugbank":["DB13224"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL374731","canonicalSmiles":"Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O","inchiKey":"IQFYYKKMVGJFEH-CSMHCCOUSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TELBIVUDINE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Sebivo","Tyzeka"],"synonyms":["2'-deoxy-l-thymidine","LDT-600","LDT600","NV-02B","Telbivudine"],"crossReferences":{"Wikipedia":["Telbivudine"],"drugbank":["DB01265"],"chEBI":["63624"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3918017","canonicalSmiles":"CC[C@@H](C(N)=O)N1C[C@H](C=C(F)F)CC1=O","inchiKey":"ANWPENAPCIFDSZ-RQJHMYQMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SELETRACETAM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Seletracetam","UCB 44212","UCB-44212"],"crossReferences":{"drugbank":["DB05885"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3989512","canonicalSmiles":"CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C","inchiKey":"DZMVCVHATYROOS-ZBFGKEHZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOBLIDOTIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Auristatin pe","Soblidotin","TZT-1027"],"crossReferences":{"drugbank":["DB12677"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3989682","canonicalSmiles":"CN(CP(=O)(O)O)c1cc([N+](=O)[O-])cc2[nH]c(=O)c(=O)[nH]c12","inchiKey":"DDOAQMGXVXFNSH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BECAMPANEL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMP-397","AMP397","Becampanel"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989829","canonicalSmiles":"CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O","inchiKey":"AGFWIZQEWFGATK-UNZHCMSXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NETILMICIN SULFATE","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1572","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Netillin","Netromycin"],"synonyms":["Netilmicin sulfate","Netilmicin sulphate","SCH 20569","SCH-20569"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and has 1 investigational indication."}
{"id":"CHEMBL3989997","drugType":"Antibody","blackBoxWarning":false,"name":"SUVRATOXUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-4893","MEDI4893","Suvratoxumab"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4072756","canonicalSmiles":"COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1","inchiKey":"FCNQMDSJHADDFT-WNSKOXEYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-5423","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD5423","Azd 5423","Azd-5423","Azd5423"],"crossReferences":{"drugbank":["DB12280"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["MONDO_0004979","EFO_0000341"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297101","canonicalSmiles":"Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\\C3=C(C(=O)[O-])N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1.[Na+]","inchiKey":"MFAWUGGPPMTWPU-INRVRKGJSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFTOBIPROLE MEDOCARIL","maximumClinicalTrialPhase":3,"parentId":"CHEMBL1652606","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAL5788","BAL5788-001","Ceftobiprole medocaril","RO 65-5788"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297333","canonicalSmiles":"CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O","inchiKey":"JGGNOCUEWOGWPL-MUUNZHRXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VB-201","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Vb 201","Vb-201"],"crossReferences":{"drugbank":["DB15259"]},"linkedTargets":{"rows":["ENSG00000137462","ENSG00000170458"],"count":2},"linkedDiseases":{"rows":["EFO_0000729","MONDO_0100096","EFO_0000676"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297630","canonicalSmiles":"CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)C(C)C)C(=O)O","inchiKey":"YEKUUBPJRPXMBM-PTCFZACGSA-N","drugType":"Protein","blackBoxWarning":false,"name":"COTADUTIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cotadutide","MEDI-0382","MEDI0382","Medi 0382","Medi0382"],"crossReferences":{"drugbank":["DB15194"]},"linkedTargets":{"rows":["ENSG00000112164","ENSG00000215644"],"count":2},"linkedDiseases":{"rows":["HP_0000083","EFO_0003095","MONDO_0005148","EFO_0001073"],"count":4},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297659","canonicalSmiles":"CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O","inchiKey":"HYPYXGZDOYTYDR-HAJWAVTHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MENAQUINONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["J39.473D","Menaquinone","Menaquinone 5","Vitamin k2(25)","Vitamin mk 5"],"crossReferences":{"drugbank":["DB15381"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297811","drugType":"Protein","blackBoxWarning":false,"name":"PR1 LEUKEMIA PEPTIDE VACCINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pr1 leukemia peptide vaccine","Pr1 vac","Proteinase 3 pr1 peptide"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4297823","drugType":"Unknown","blackBoxWarning":false,"name":"SC-004","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADC SC-004","Antibody-drug conjugate sc-004","SC-004","SC004","Sc-004"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297951","drugType":"Unknown","blackBoxWarning":false,"name":"COAGULATION FACTOR X HUMAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Coagulation factor x","Coagulation factor x human","Coagulation factor x, human","Factor x","Human coagulation factor x","Human factor x"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297987","drugType":"Antibody","blackBoxWarning":false,"name":"ENAPOTAMAB VEDOTIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Axl-107-mmae","Enapotamab vedotin","Humax axl adc","Humax-axl-adc"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4298078","drugType":"Unknown","blackBoxWarning":false,"name":"PYRIDOXAMINE DIHYDROCHLORIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-21278","Pyridorin","Pyridoxamine dihydrochloride","Pyridoxamine hydrochloride"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL434785","canonicalSmiles":"N[C@@H](C(=O)O)C1Cc2ccccc2C1","inchiKey":"GUDHMDVRURNAHL-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL434785","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04061"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL447868","canonicalSmiles":"O=C([O-])c1ccccc1O.[Na+]","inchiKey":"ABBQHOQBGMUPJH-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM SALICYLATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alysine","Sod sal"],"synonyms":["Enterosalicyl","Kerasalicyl","NSC-202167","Natrii salicylas","Natrum salicylicum","Salicylate sodium","Salicylic acid sodium salt","Sodium Salicylate","Sodium salicylate"],"crossReferences":{"PubChem":["144207609","26748246"],"Wikipedia":["Sodium_salicylate"],"chEBI":["9180"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain and has 3 investigational indications."}
{"id":"CHEMBL451855","canonicalSmiles":"NC(=O)c1c[se]c([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)n1","inchiKey":"SKNBJMQZTZPCPF-QZTLEVGFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Selenazole-4-Carboxamide Adenine Dinucleotide","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Selenazole-4-Carboxamide Adenine Dinucleotide"],"crossReferences":{"drugbank":["DB03070"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594259","drugType":"Small molecule","blackBoxWarning":false,"name":"TIOMOLIBDATE CHOLINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALXN-1840","ALXN1840","ATN-224","Alxn1840","Atn-224","Bis(choline) tetrathiomolybdate","Bis(choline)tetrathiomolybdate","Bis-choline tetrathiomolybdate","Choline tetrathiomolybdate","Tiomolibdate choline","WTX-101","WTX101","Wtx-101","Wtx101"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4594265","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"GIVOSIRAN SODIUM","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Givlaari"],"synonyms":["Givosiran sodium"],"crossReferences":{"DailyMed":["givosiran%20sodium"]},"linkedTargets":{"rows":["ENSG00000023330"],"count":1},"linkedDiseases":{"rows":["Orphanet_95157","EFO_0001421"],"count":2},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for acute hepatic porphyria and liver disease."}
{"id":"CHEMBL4594380","canonicalSmiles":"[2H]c1c([2H])c([2H])c2c([nH]c(=O)n2CCCN2CCC(n3c(=O)[nH]c4cc(Cl)ccc43)CC2)c1[2H]","inchiKey":"FGXWKSZFVQUSTL-GYABSUSNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEUDOMPERIDONE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL219916","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CIN-102","Deudomperidone"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4594458","drugType":"Unknown","blackBoxWarning":false,"name":"ANTITHROMBIN GAMMA","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acoalan","Afucosylated antithrombin","Antithrombin gamma"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4594601","drugType":"Unknown","blackBoxWarning":false,"name":"RO-5429083","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RG 7356","RG-7356","RO-5429083","RO5429083","Ro-5429083","Ro5429083"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4802196","drugType":"Unknown","blackBoxWarning":false,"name":"ERAGIDOMIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CC-90009","Cc-90009","Eragidomide"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL485945","canonicalSmiles":"NCCNc1nnc(-c2ccc(F)c(F)c2Nc2ccc(I)cc2F)o1","inchiKey":"FPDWDLAITHFTTP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL485945","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08130"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL513909","canonicalSmiles":"CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1","inchiKey":"XQVVPGYIWAGRNI-JOCHJYFZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BI-2536","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BI-2536","Bi 2536","Bi-2536"],"linkedTargets":{"rows":["ENSG00000166851"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003860","EFO_0000702","EFO_0000673","EFO_0000222","EFO_0000574","EFO_0003060"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL564829","canonicalSmiles":"CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2","inchiKey":"RXZMYLDMFYNEIM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MILCICLIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Milciclib","PHA 848125","PHA-848125","Pha-848125"],"childChemblIds":["CHEMBL4297668","CHEMBL561564"],"linkedTargets":{"rows":["ENSG00000123374","ENSG00000135446","ENSG00000170312","ENSG00000198400"],"count":4},"linkedDiseases":{"rows":["EFO_0000616","EFO_1000576","EFO_1000581","EFO_0000182"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL571546","canonicalSmiles":"O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1","inchiKey":"HUNGUWOZPQBXGX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIRBANIBULIN","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Klisyri"],"synonyms":["KX-01","KX-2-391","KX-2391","KX2-391","KX2391","Kx2-391","Tirbanibulin"],"crossReferences":{"PubChem":["164339429"],"drugbank":["DB06137"]},"childChemblIds":["CHEMBL4594279"],"linkedTargets":{"rows":["ENSG00000197122"],"count":1},"linkedDiseases":{"rows":["EFO_0000574","EFO_0000222","MONDO_0008315","EFO_0002496"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for actinic keratosis and has 3 investigational indications."}
{"id":"CHEMBL571987","canonicalSmiles":"CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1","inchiKey":"MCPUZZJBAHRIPO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LERSIVIRINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lersivirine","UK-453,061","UK-453061"],"crossReferences":{"drugbank":["DB11649"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL576982","canonicalSmiles":"CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1","inchiKey":"CVWXJKQAOSCOAB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUIZARTINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AC-010220","AC-220","AC010220","AC220","ASP-2689","Ac-220","Quizartinib"],"crossReferences":{"PubChem":["137275856"],"drugbank":["DB12874"],"chEBI":["90217"]},"childChemblIds":["CHEMBL2105709"],"linkedTargets":{"rows":["ENSG00000134853","ENSG00000165731","ENSG00000113721","ENSG00000157404","ENSG00000182578","ENSG00000122025"],"count":6},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_0000220","EFO_0001421","EFO_0000222"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL593429","canonicalSmiles":"NC(=O)NC1NC(=O)NC1=O","inchiKey":"POJWUDADGALRAB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALLANTOIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Allantoin","Alwextin","Cordianine","Dl-allantoin","Idelalisib metabolite m1a","NSC-7606","Psoralon","Sd 101","Septalan"],"crossReferences":{"PubChem":["144203946","144209285","144213229","170465460","26665884","26748398","73440"],"Wikipedia":["Allantoin"],"drugbank":["DB11100"],"chEBI":["15676"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL601773","canonicalSmiles":"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O","inchiKey":"DEQITUUQPICUMR-HJPBWRTMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIHYDROERGOCRISTINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["9,10-dihydroergocristine","Dihydroergocristine","GNF-PF-3462"],"crossReferences":{"PubChem":["124883203","124883205","144205574","144206666","26751531","50104109","50104110","90341070"],"drugbank":["DB13345"],"chEBI":["59912"]},"childChemblIds":["CHEMBL1255837"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL72232","canonicalSmiles":"O=C(c1ccc(O)cc1)N1CCc2c(n(Cc3ccc(O)cc3)c3ccccc23)C1","inchiKey":"ADXYEWMDAGIULV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL72232","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04030"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL76739","canonicalSmiles":"C[C@H](C(=O)O)[C@H](N)C(=O)O","inchiKey":"LXRUAYBIUSUULX-HRFVKAFMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL76739","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04538"],"chEBI":["47980"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL76768","canonicalSmiles":"O=C(O)C1=CCCNC1","inchiKey":"QTDZOWFRBNTPQR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUVACINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Guvacine"],"crossReferences":{"PubChem":["11111208","11113419","90340745"],"drugbank":["DB08848"],"chEBI":["5576"]},"childChemblIds":["CHEMBL1256362"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL783","canonicalSmiles":"CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1","inchiKey":"OELFLUMRDSZNSF-BRWVUGGUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NATEGLINIDE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nateglinide","Starlix","Starsis"],"synonyms":["A-4166","AY-4166","AY4166","D-nateglinide","DJN 608","DJN-608","NSC-758695","Nateglinide","SDZ DJN 608","SDZ-DJN-608","Senaglinide"],"crossReferences":{"DailyMed":["nateglinide"],"PubChem":["144204985","170464822","26719880"],"drugbank":["DB00731"],"chEBI":["31897"]},"linkedTargets":{"rows":["ENSG00000187486","ENSG00000006071"],"count":2},"linkedDiseases":{"rows":["MONDO_0005148","EFO_0000400"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for diabetes mellitus and type 2 diabetes mellitus."}
{"id":"CHEMBL85860","canonicalSmiles":"CC(C)(C)c1cc(NC(=O)Nc2ccc(Cl)cc2)n(-c2ccccc2)n1","inchiKey":"XIWRCSVXKPGGAJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL85860","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01807"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL89506","canonicalSmiles":"CCCCCCCCSCC(=O)C(F)(F)F","inchiKey":"WMQHRXUKAYSPPK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL89506","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08612"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL9509","canonicalSmiles":"COc1cc(C2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3OC2CO)ccc1O","inchiKey":"SEBFKMXJBCUCAI-DBMPWETRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SILIBININ","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Legalon","Silibin","Silibinin","Silibinin a-silibinin b mixt.","Silliver","Silybin","Silybine","Silymarin"],"crossReferences":{"Wikipedia":["Silibinin"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
